US Patent 11890325 Therapeutic uses of dulaglutide
Patent 11890325 was granted and assigned to Eli Lilly and Company on February, 2024 by the United States Patent and Trademark Office.
All edits
Edits on 9 Feb, 2024
Golden AI
Edits made to:
Infobox (+19 properties)
Article (+379 characters)
US Patent 11890325 Therapeutic uses of dulaglutide
Article
Patent abstract
The present invention relates to methods for reducing the risk of major adverse cardiovascular events in type 2 diabetes mellitus (T2DM) patients with multiple cardiovascular risk factors without established cardiovascular disease or with established cardiovascular disease comprising administering the glucagon like peptide-1 (GLP-1) receptor agonist dulaglutide.
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
Patent Inventor Names
David Bradley Woodward0
Jeffrey S. Riesmeyer0
Date of Patent
February 6, 2024
0Patent Application Number
175996210
Date Filed
November 4, 2019
0Patent Citations
Patent Primary Examiner
CPC Code
Find more entities like US Patent 11890325 Therapeutic uses of dulaglutide
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
